Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. reports developments in molecular diagnostics, including its patented platform for designing molecular diagnostic tests and its Co-Dx PCR platform. Company news commonly covers clinical and regulatory disclosures, commercialization activity through CoSara and CoMira joint ventures, intellectual property and technology updates, and operating and financial results.
Recurring updates also include material agreements, governance matters, capital-structure actions, and securities-listing developments. The company’s public disclosures connect its diagnostic-test pipeline, platform development, and commercialization strategy with financing, shareholder approvals, and other corporate actions.
Co-Diagnostics (Nasdaq: CODX) signed an exclusive distribution agreement with its longstanding Mexico partner for the Co-Dx™ PCR point-of-care platform, including PCR Pro® and related test kits. The deal extends the relationship five years and supports Latin American commercialization ahead of required regulatory authorizations.
The partner has generated over $18 million in revenue for Co-Diagnostics since 2020 through Logix Smart® PCR tests and lab equipment sales. Logix Smart COVID-19 PCR tests accounted for over 50% of Mexico’s COVID-19 tests through 2021, based on public data.
Co-Diagnostics (Nasdaq: CODX) and joint venture CoSara reported progress in developing Ebola PCR tests and expanding the Co-Dx™ PCR point-of-care platform.
The program includes a pan-Ebola assay to detect multiple ebolavirus species and a multiplex assay to differentiate Sudan, Taï Forest, Zaire, and Bundibugyo strains, with planned point-of-care, blood-based testing on Co-Dx PCR Pro®, all subject to further development and regulatory review.
Co-Diagnostics (Nasdaq: CODX) announced an advanced PCR assay development strategy for Bundibugyo virus (BDBV), the ebolavirus strain driving the 2026 outbreak in DRC and Uganda. Partnering with joint venture CoSara, the plan targets faster international deployment, pan-Ebola detection options, and support for point-of-care PCR workflows, subject to regulatory review.
Co-Diagnostics (Nasdaq: CODX) entered a securities purchase agreement for a $3.0 million private placement priced at-the-market under Nasdaq rules. The deal covers common stock or pre-funded warrants plus accompanying warrants.
The offering includes immediate-exercise five-year warrants and is expected to close on or about May 21, 2026.
Co-Diagnostics (Nasdaq: CODX) announced completion of its assay development strategy for Bundibugyo virus (BDBV), linked to the current Ebola outbreak in the Democratic Republic of the Congo and Uganda.
The company plans to use its Co-Dx PCR point-of-care platform, which remains under regulatory review and not yet for sale.
Co-Diagnostics (Nasdaq: CODX) reported Q1 2026 revenue of $0.15 million, up from $0.05 million in Q1 2025. Operating expenses were $9.2 million and net loss was $9.1 million, or $4.06 per share. Cash was $8.2 million on March 31, 2026.
Key updates include an Indian CDSCO license and ISO 13485 certification for the CoSara PCR Pro® instrument, South Asia territory expansion lifting TAM to about $13 billion, completion of upper respiratory clinical enrollment, TB study preparations in India, and advancement of a CoMira manufacturing facility in Saudi Arabia.
Co-Diagnostics (Nasdaq: CODX) joint venture CoMira has finalized a lease for a ~14,400 sq ft turnkey manufacturing facility in Sudair Industrial City, Saudi Arabia, advancing localized production of PCR instruments, laboratory equipment and medical consumables.
The lease follows an approved industrial land allocation and aims to support capital-efficient operational readiness, regional distribution across KSA and MENA, and alignment with Saudi Vision 2030, subject to required regulatory clearances.
Co-Diagnostics (Nasdaq: CODX) will release its first quarter 2026 financial results on Thursday, May 14, 2026 after market close. A live conference call and webcast will follow at 4:30 p.m. ET with CEO Dwight Egan, CFO Brian Brown, and Head of Investor Relations Andrew Benson.
The webcast will be available at ir.co-dx.com on the Events & Webcasts page; a recorded replay will be posted later.
Co-Diagnostics (NASDAQ: CODX) was invited to present its Co-Dx MTB test on the Co-Dx PCR platform at the Stop TB Partnership Summit in Washington, D.C. on April 17, 2026.
The company will present at a roundtable with U.S. government agencies and private-sector stakeholders. According to the company, the platform aligns with recent WHO guidance on near-point-of-care molecular diagnostics and tongue-swab testing. The Co-Dx PCR platform remains under FDA and other regulatory review and is not yet available for sale.
Co-Diagnostics (NASDAQ:CODX) will present at ESCMID Global 2026, April 17-21 in Munich, Germany, showcasing its CE-IVD testing solutions and the upcoming Co-Dx PCR platform.
Company representatives will meet global customers and distributors at Booth #G55. The Co-Dx PCR platform is under regulatory review and not yet for sale.